Pieris validates VEGF blocker in preclinical models

Pieris AG, a German biopharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, says it has made  significant progress in the development of its Anticalin candidate  PRS-050, a potent vascular endothelial growth factor antagonist with  potentially-broad applicability.

Having successfully demonstrated the mode of action of PRS-050 in vitro  and in vivo, Pieris has now validated the efficacy of the Anticalin  product candidate in several preclinical models. Amongst those tested,  Dynamic Contrast-Enhanced Magnetic Resonance Imaging has been  established and validated to monitor immediate treatment effects in the  upcoming Phase I trial.

Production process parameters for Good Manufacturing Process production  standards for PRS-050 have also been clearly defined. Initial toxicology  results have shown that the drug is very well tolerated. Pieris has  fulfiled critical speed and capacity goals in producing Anticalins as  clinical product candidates.